Rituximab: Current status as therapy for malignant and Benign hematologic disorders

Keyphrases

• Antibody Targeting 20%
• Autoimmune Hemolytic Anemia 20%
• B-cell Antigens 20%
• Cancer Treatment 20%
• CD20 20%
• CD20-negative 20%
• Chemotherapy 20%
• Chimeric Monoclonal Antibody 20%
• Chronic Lymphocytic Leukemia 20%
• Clinical Application 20%
• Clinical Conditions 20%
• Clinical Development 20%
• Clinical Trials 20%
• Efficacy Data 20%
• First Approval 20%
• Hematological Diseases 100%
• Hematology 20%
• Immune Thrombocytopenic Purpura 20%
• Induction Therapy 20%
• Lymphoma 20%
• Maintenance Therapy 20%
• Malignant Hematological Diseases 20%
• Monoclonal Antibody 20%
• Monotherapy 20%
• Nonmalignant 20%
• Oncology 20%
• Rituximab 100%

Medicine and Dentistry

• B Cell 20%
• B-Cell Chronic Lymphocytic Leukemia 20%
• Blood Disorder 100%
• Cancer Treatment 20%
• CD20 20%
• CD20 Antigen 20%
• Cell Antigen 20%
• Clinical Trial 20%
• Evans Syndrome 20%
• Hematology 20%
• Idiopathic Thrombocytopenic Purpura 20%
• Maintenance Therapy 20%
• Monoclonal Antibody 40%
• Monotherapy 20%
• Oncology 20%
• Rituximab 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Autoimmune Hemolytic Anemia 20%
• CD20 Antigen 20%
• Cell Antigen 20%
• Chemotherapy 20%
• Chronic Lymphatic Leukemia 20%
• Clinical Trial 20%
• Idiopathic Thrombocytopenic Purpura 20%
• Malignant Neoplasm 20%
• Monoclonal Antibody 40%
• Monotherapy 20%
• Rituximab 100%